Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:36048.

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy

Toril Holien _, Kristine Misund, Oddrun Elise Olsen, Katarzyna Anna Baranowska, Glenn Buene, Magne Børset, Anders Waage and Anders Sundan

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:22698-22705. https://doi.org/10.18632/oncotarget.4245

Metrics: PDF 1053 views  |   HTML 1092 views  |   ?  


Abstract

Toril Holien1, Kristine Misund1, Oddrun Elise Olsen1, Katarzyna Anna Baranowska1, Glenn Buene1, Magne Børset1,2, Anders Waage1,3, Anders Sundan1,4

1K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

2Department of Immunology and Transfusion Medicine, St. Olav’s University Hospital, Trondheim, Norway

3Department of Hematology, St. Olav’s University Hospital, Trondheim, Norway

4CEMIR (Centre of Molecular Inflammation Research), Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

Correspondence to:

Toril Holien, e-mail: toril.holien@ntnu.no

Keywords: oncology, carcinogenesis, molecular and cellular biology, signal transduction, cell cycle

Received: March 09, 2015     Accepted: May 20, 2015     Published: June 02, 2015

ABSTRACT

In multiple myeloma, elevated MYC expression is related to disease initiation and progression. We found that in myeloma cell lines, MYC gene amplifications were common and correlated with MYC mRNA and protein. In primary cell samples MYC mRNA levels were also relatively high; however gene copy number alterations were uncommon. Elevated levels of MYC in primary myeloma cells have been reported to arise from complex genetic aberrations and are more common than previously thought. Thus, elevated MYC expression is achieved differently in myeloma cell lines and primary cells. Sensitivity of myeloma cell lines to the MYC inhibitor 10058-F4 correlated with MYC expression, supporting that the activity of 10058-F4 was through specific inhibition of MYC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4245